OptimizeRx (OPRX)
(Delayed Data from NSDQ)
$12.30 USD
-0.27 (-2.15%)
Updated May 23, 2024 04:00 PM ET
After-Market: $12.32 +0.02 (0.16%) 4:52 PM ET
2-Buy of 5 2
D Value B Growth C Momentum C VGM
Price, Consensus and EPS Surprise
OPRX 12.30 -0.27(-2.15%)
Will OPRX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for OPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for OPRX
Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?
Open Text (OTEX) Q3 Earnings Meet Estimates
OPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)
Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)
Bruker (BRKR) Q4 Earnings and Revenues Top Estimates
Other News for OPRX
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Nasdaq Surges 150 Points; Retail Sales Flat For April
BioCryst Pharmaceuticals, T2 Biosystems, Annovis Bio among healthcare movers
Expert Ratings For OptimizeRx